In particular, in colorectal cancer models, IPA reverses the state of immune tolerance caused by aberrant IDO1 activity by restoring the tryptophan-indole metabolic axis, providing a theoretical basis for cancer immunotherapy targeting metabolic remodeling. This evidence concerns the gene IDO1 and cancer.